BR112020003735A2 - método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais - Google Patents
método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais Download PDFInfo
- Publication number
- BR112020003735A2 BR112020003735A2 BR112020003735-4A BR112020003735A BR112020003735A2 BR 112020003735 A2 BR112020003735 A2 BR 112020003735A2 BR 112020003735 A BR112020003735 A BR 112020003735A BR 112020003735 A2 BR112020003735 A2 BR 112020003735A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral
- arginine
- mimetic
- analog
- tranexamic acid
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title claims abstract description 233
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 40
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 33
- 230000009385 viral infection Effects 0.000 title claims abstract description 31
- 238000011161 development Methods 0.000 title claims abstract description 23
- 230000001684 chronic effect Effects 0.000 title claims abstract description 20
- 230000009467 reduction Effects 0.000 claims abstract description 127
- 241000700605 Viruses Species 0.000 claims abstract description 110
- 239000004472 Lysine Substances 0.000 claims abstract description 88
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 87
- 150000001413 amino acids Chemical class 0.000 claims abstract description 56
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 230000002265 prevention Effects 0.000 claims abstract description 24
- 230000001629 suppression Effects 0.000 claims abstract description 9
- 239000003124 biologic agent Substances 0.000 claims abstract description 6
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 307
- 229960000401 tranexamic acid Drugs 0.000 claims description 307
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 140
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 68
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 37
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 28
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 230000001052 transient effect Effects 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- 230000000306 recurrent effect Effects 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 7
- 230000003042 antagnostic effect Effects 0.000 claims description 7
- -1 inhalation Substances 0.000 claims description 7
- 229960002684 aminocaproic acid Drugs 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 229940051866 mouthwash Drugs 0.000 claims 2
- 231100000223 dermal penetration Toxicity 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 266
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 167
- 229930064664 L-arginine Natural products 0.000 description 164
- 235000014852 L-arginine Nutrition 0.000 description 164
- 229960002885 histidine Drugs 0.000 description 157
- 239000004475 Arginine Substances 0.000 description 106
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 106
- 235000009697 arginine Nutrition 0.000 description 106
- 235000018977 lysine Nutrition 0.000 description 63
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 55
- 235000014304 histidine Nutrition 0.000 description 55
- 229940024606 amino acid Drugs 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 50
- 230000000840 anti-viral effect Effects 0.000 description 35
- 230000007502 viral entry Effects 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 33
- 239000002253 acid Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 32
- 239000002054 inoculum Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 26
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 25
- 239000002609 medium Substances 0.000 description 25
- 230000010076 replication Effects 0.000 description 23
- 241001529453 unidentified herpesvirus Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 238000011156 evaluation Methods 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000029812 viral genome replication Effects 0.000 description 17
- 208000004898 Herpes Labialis Diseases 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 206010067152 Oral herpes Diseases 0.000 description 12
- 230000036512 infertility Effects 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 10
- 238000009533 lab test Methods 0.000 description 10
- 230000000069 prophylactic effect Effects 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 229940124977 antiviral medication Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 101100042265 Caenorhabditis elegans sem-2 gene Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 101100042258 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sem-1 gene Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 3
- 229960000735 docosanol Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 241001455657 Human betaherpesvirus 6A Species 0.000 description 2
- 102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 description 2
- 101710155665 Mesencephalic astrocyte-derived neurotrophic factor Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550656P | 2017-08-27 | 2017-08-27 | |
| US62/550656 | 2017-08-27 | ||
| US201862664555P | 2018-04-30 | 2018-04-30 | |
| US62/664555 | 2018-04-30 | ||
| PCT/US2018/046023 WO2019045989A1 (en) | 2017-08-27 | 2018-08-09 | METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020003735A2 true BR112020003735A2 (pt) | 2020-09-01 |
Family
ID=65525881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020003735-4A BR112020003735A2 (pt) | 2017-08-27 | 2018-08-09 | método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11413279B2 (https=) |
| EP (2) | EP3672584A4 (https=) |
| JP (3) | JP2020531586A (https=) |
| KR (1) | KR102706114B1 (https=) |
| CN (1) | CN111315374A (https=) |
| AU (2) | AU2018324427B2 (https=) |
| BR (1) | BR112020003735A2 (https=) |
| CA (1) | CA3073685A1 (https=) |
| MX (2) | MX2020002156A (https=) |
| WO (1) | WO2019045989A1 (https=) |
| ZA (1) | ZA202001472B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023505641A (ja) * | 2019-10-29 | 2023-02-10 | トラネキサミック テクノロジーズ， エルエルシー | 有効性の増強のための合成リジンアナログ、誘導体、模倣物又はプロドラッグと医薬剤との相乗的組合せ |
| EP4103167A4 (en) * | 2020-02-14 | 2024-03-13 | Tranexamic Technologies, LLC | METHODS AND COMPOSITIONS FOR THE ANTIMICROBIAL USE OF SYNTHETIC LYSINE ANALOGS, DERIVATIVES, MIMETICS AND PRODRUGS |
| JP7830159B2 (ja) * | 2021-02-26 | 2026-03-16 | ライオン株式会社 | コロナウイルスの細胞侵入抑制剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2203827A1 (en) * | 1994-10-28 | 1996-05-09 | Gerard Voerman | Novel family of protease inhibitors, and other biologic active substances |
| WO2000037071A1 (en) * | 1998-12-21 | 2000-06-29 | Aps Kbus 8 Nr. 4788 | Topical treatment of skin disease |
| ES2156731B1 (es) | 1999-05-31 | 2002-02-16 | Grifols Grupo Sa | Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano. |
| US7056947B2 (en) | 2002-07-05 | 2006-06-06 | Georgia Tech Research Corp. | Aza-peptide epoxides |
| WO2004032915A1 (ja) * | 2002-10-11 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | 抗インフルエンザウイルス剤 |
| JP2008115168A (ja) * | 2006-10-12 | 2008-05-22 | Daiichi Sankyo Healthcare Co Ltd | 抗アデノウイルス剤 |
| CA2742817A1 (en) * | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
| JP2010189301A (ja) * | 2009-02-17 | 2010-09-02 | Toshihito Eto | 新型インフルエンザ感染症に対する医薬組成物およびその利用 |
| US20120082677A1 (en) * | 2010-10-01 | 2012-04-05 | Sherif Salah Abdul Aziz | Compositions for the treatment of hcv and hbv |
| US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| CN103405384B (zh) * | 2013-09-01 | 2015-05-13 | 吴静 | 氨甲环酸的药物组合物 |
-
2018
- 2018-08-09 KR KR1020207008860A patent/KR102706114B1/ko active Active
- 2018-08-09 US US16/610,504 patent/US11413279B2/en active Active
- 2018-08-09 CN CN201880070088.0A patent/CN111315374A/zh active Pending
- 2018-08-09 WO PCT/US2018/046023 patent/WO2019045989A1/en not_active Ceased
- 2018-08-09 BR BR112020003735-4A patent/BR112020003735A2/pt unknown
- 2018-08-09 JP JP2020532845A patent/JP2020531586A/ja not_active Withdrawn
- 2018-08-09 MX MX2020002156A patent/MX2020002156A/es unknown
- 2018-08-09 AU AU2018324427A patent/AU2018324427B2/en not_active Ceased
- 2018-08-09 CA CA3073685A patent/CA3073685A1/en active Pending
- 2018-08-09 EP EP18850491.4A patent/EP3672584A4/en not_active Withdrawn
- 2018-08-09 EP EP25197729.4A patent/EP4681713A2/en active Pending
-
2020
- 2020-02-26 MX MX2023009499A patent/MX2023009499A/es unknown
- 2020-03-09 ZA ZA2020/01472A patent/ZA202001472B/en unknown
-
2022
- 2022-05-25 US US17/824,602 patent/US20220288050A1/en not_active Abandoned
-
2023
- 2023-05-30 JP JP2023088440A patent/JP2023123440A/ja not_active Withdrawn
-
2024
- 2024-06-06 AU AU2024203839A patent/AU2024203839A1/en active Pending
-
2025
- 2025-08-01 JP JP2025129144A patent/JP2025166032A/ja active Pending
- 2025-09-11 US US19/326,649 patent/US20260007649A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11413279B2 (en) | 2022-08-16 |
| EP3672584A1 (en) | 2020-07-01 |
| MX2020002156A (es) | 2020-07-20 |
| JP2025166032A (ja) | 2025-11-05 |
| EP4681713A2 (en) | 2026-01-21 |
| US20200323837A1 (en) | 2020-10-15 |
| KR102706114B1 (ko) | 2024-09-11 |
| JP2023123440A (ja) | 2023-09-05 |
| KR20200052310A (ko) | 2020-05-14 |
| AU2024203839A1 (en) | 2024-06-27 |
| MX2023009499A (es) | 2023-08-23 |
| AU2018324427B2 (en) | 2024-03-07 |
| ZA202001472B (en) | 2022-05-25 |
| EP3672584A4 (en) | 2021-05-05 |
| US20260007649A1 (en) | 2026-01-08 |
| JP2020531586A (ja) | 2020-11-05 |
| CN111315374A (zh) | 2020-06-19 |
| AU2018324427A1 (en) | 2020-04-09 |
| WO2019045989A1 (en) | 2019-03-07 |
| CA3073685A1 (en) | 2019-03-07 |
| US20220288050A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hulisz | Efficacy of zinc against common cold viruses: an overview | |
| US9387227B2 (en) | Method for treatment of sores and lesions of the skin | |
| US20260007649A1 (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
| SA96160590B1 (ar) | تركيبة صيدلانية | |
| JPS59130223A (ja) | 相乗作用を示す抗ヘルペス組成物 | |
| BR122023026038A2 (pt) | Usos de um ácido e de um modulador de autofagia e de lipofagia | |
| US10052328B2 (en) | Therapeutic composition to treat lesions caused by Herpes Simplex Virus | |
| ITRM20060163A1 (it) | Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex | |
| WO2021198940A1 (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| DK2374461T3 (en) | Piroxicam for the prophylactic and therapeutic treatment of herpes infections | |
| PT653939E (pt) | Utilizacao de um veneno de himenoptero para o fabrico de um medicamento para o tratamento de infeccoes por virus de adn | |
| Wu et al. | IcyHot analgesic topical cream limits cardiac injury in rodents | |
| HK40026056A (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
| SG192966A1 (en) | The treatment of viral infections | |
| BR112017024399B1 (pt) | Composição farmacêutica antiviral de uso tópico | |
| US11819508B2 (en) | Miltefosine for the treatment of viral infections including covid-19 | |
| RU2819719C2 (ru) | Средство для наружного применения с противовирусным действием | |
| US20250177335A1 (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for modulating autophagy and lipophagy | |
| BR102020014414B1 (pt) | Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes | |
| BR102022021083A2 (pt) | Composição alimentar, uso da referida composição para aumentar a imunidade e ter capacidade de desintoxicação para melhorar fatores de estilo de vida, produto alimentar que compreende a referida composição e kit | |
| US10045952B2 (en) | Anti-Viral Compound and Composition | |
| US20230414557A1 (en) | New therapy concept for the treatment of corona infections, especially covid-19 infections | |
| WO2021224659A1 (es) | Composición farmacéutica y kit-de-partes para ser usados frente a infecciones causadas por corona virus | |
| CN114929212A (zh) | 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合 | |
| BR102020014414A2 (pt) | Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |